The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
This summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review to determine if the medications are unaffordable and whether to cap what health plans and consumers pay for them.
The class action lawsuit filed six years ago against the drugmaker, which alleged systematic overpricing, will set up a $13.5 million settlement fund for those who pay out of pocket.
Sen. Bernie Sanders, chair of the Senate Health, Education, Labor and Pensions Committee, made this bold statement, which some say contains elements of truth, however, it's why he's made lowering drug costs a top priority.
Amgen had sought to collect millions in damages from Sanofi because the pharmaceutical company makes a rival drug called Praluent, which works by a similar mechanism as Amgen's Repatha, in a case dating back to 2014.
A Senate panel advanced four bills aimed at reforming pharmacy benefit manager practices and improving generic drug competition, one day after the senators heard input from major PBM and pharma executives.
Insulin and pharmacy benefit management company executives testified before the Senate Health, Education, Labor and Pensions Committee this week in Washington in preparation for a vote on PBM legislation.
At the committee level, there is a lot of bipartisan activity for health care reform for 2023 that includes PBM reforms and insulin caps in the commercial market, as well as regulatory guidance on the new retirement bill SECURE 2.0.